Insmed Incorporated

Both ARIKAYCE and BRINSUPRI treat chronic conditions requiring ongoing therapy, and ARIKAYCE delivered consistent year-over-year revenue growth across all geographies from FY2020 through FY2025. Revenue visibility is supported by patient persistence on specialty therapy but lacks a formal backlog or subscription structure common to higher-predictability businesses.

Insmed has two commercial products in adjacent respiratory rare-disease markets; BRINSUPRI is projected to generate at least $1 billion in 2026, making it the dominant revenue driver while ARIKAYCE generated $433.8 million in FY2025. The pipeline includes TPIP in Phase 3 for PAH and related conditions, but this remains pre-revenue, and the current portfolio lacks meaningful diversification across end markets or therapeutic areas.

The U.S. accounts for roughly 70-75% of combined product revenue across ARIKAYCE and BRINSUPRI in FY2025, with Japan contributing approximately 22% of ARIKAYCE revenues in FY2024 and Europe a small but growing share. BRINSUPRI received EU approval in November 2025 but generates primarily U.S. revenues, leaving the company highly dependent on the U.S. reimbursement landscape.

Insmed's existing commercial infrastructure built for ARIKAYCE is being leveraged for the BRINSUPRI launch, allowing significant revenue growth without proportional headcount expansion in sales. R&D spending remains substantial as the company funds multiple Phase 3 programs simultaneously, limiting near-term operating leverage improvement.

Both ARIKAYCE and BRINSUPRI address conditions where patients have no approved alternatives, driving high persistence once therapy is initiated; MAC lung disease and NCF bronchiectasis are chronic, progressive conditions for diagnosed patients. Revenue is transactional (specialty pharmacy fills) rather than contractual, creating dependence on continued new patient acquisition alongside existing cohort retention.